Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT00465959

Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease

Safety, Tolerability, Pharmacokinetics, and Efficacy of Single Inhaled Administrations of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease

Sponsor: Alkermes, Inc.

Conditions Chronic Obstructive Pulmonary Disease

Interventions Placebo trospium chloride inhalation powder (TrIP)

Updated 7 times since 2017 Last updated: Dec 3, 2013 Started: Apr 30, 2007 Primary completion: Jun 30, 2007 Completion: Jun 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00465959, this PHASE1/PHASE2 trial focuses on Chronic Obstructive Pulmonary Disease and remains completed. Sponsored by Alkermes, Inc., it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alkermes, Inc.
Endo Pharmaceuticals

Data source: Endo Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Spartanburg, United States